Company Overview - Cooper Companies was founded in 1958 and has been listed on the S&P 500 since 2016 [1] - The company operates under two main business units: CooperVision and CooperSurgical [1] - CooperVision is the leading contact lens company globally, ranked 1 in terms of wearers and 2 in revenue [1] - CooperSurgical specializes in fertility and women's health care, focusing on non-pharmaceutical medical devices [1] Employee and Market Reach - The company employs over 15,000 individuals worldwide [2] - More than 50 million people use Cooper's products, including contact lenses and women's health care products [2] - Approximately 42 million patients annually wear Cooper's contact lenses [2] - CooperVision accounts for about two-thirds of the company's consolidated revenues [2]

Summary of The Cooper Companies FY Conference Call Company Overview - **Company**: The Cooper Companies (NasdaqGS: COO) - **Founded**: 1958 - **S&P 500 Inclusion**: Since 2016 - **Business Units**: - **CooperVision**: Leading contact lens company, number one in wearers and number two in revenue - **CooperSurgical**: Focused on fertility and women's healthcare, leading in non-pharma medical devices [1][2] Key Financial Metrics - **Employees**: Over 15,000 globally - **Product Users**: Over 50 million, with 42 million annual contact lens wearers - **Revenue Composition**: CooperVision accounts for about two-thirds of consolidated revenues - **Historical Revenue Growth**: 10-year growth rate of 8.6% [2][3] Growth Insights - **CooperVision Growth**: Primarily organic growth at 6.3%, with the contact lens market growing mid-single digits annually - **CooperSurgical Growth**: Approximately 16%, driven by acquisitions [3][4] - **Market Trends**: - Contact lens market growth projected at 4%-6% annually - Fertility market growth in mid-single digits, with potential for double-digit growth in the past [4][13] Financial Guidance - **Non-GAAP EPS Guidance**: $1.02-$1.04 for Q1 and $4.45-$4.60 for the full year - **Free Cash Flow Guidance**: $5.75-$6.25 billion, with expectations of $2.2 billion in free cash flow over the next fiscal year [5][6] Strategic Priorities - **Focus on Organic Growth**: Transitioning from heavy investment to driving organic growth and operational efficiency - **Cost Management**: Significant reorganization to reduce costs and improve operational efficiency [7][9] - **AI Integration**: Utilizing AI for inventory optimization and management [10] Market Dynamics - **Contact Lens Market**: - 35% of the global population is myopic, projected to reach 50% by 2050 - Major competitors: J&J (36% market share), CooperVision (27%), Alcon (25%) [13][14] - Shift towards daily lenses driving revenue growth, with daily wearers generating 2.5 times more revenue than monthly wearers [15][16] - **Fertility Market**: - Global market valued at approximately $3 billion, with one in six experiencing infertility - Growth driven by delayed childbirth and increasing insurance support for fertility treatments [26][27] Product Innovations - **New Product Launches**: - MiSight: FDA-approved contact lens for myopia management - MyDay MiSight: Daily silicone hydrogel lens with myopia control technology [21][22][24] - **Expansion Plans**: Launching new products in Europe and Asia, including MyDay Energys and MyDay Multifocal [24][25] Capital Allocation Strategy - **Share Repurchase Program**: Increased from $1 billion to $2 billion, with plans to consistently allocate a portion of free cash flow to buybacks [11][33] - **Investment Focus**: Transitioning from acquisitions to leveraging past investments for growth and shareholder value [11][33] Market Outlook - **2026 Guidance**: Expectation of improved performance in both CooperVision and CooperSurgical, with a focus on regaining traditional growth rates in the fertility market [45][46] - **Regional Performance**: Strong consumer behavior in the Americas, with challenges in Asia-Pac but expected improvements [47][48] Strategic Review - **Ongoing Evaluation**: Conducting a strategic review to assess the potential separation of CooperVision and CooperSurgical, considering synergies and market positioning [36][38][39] Conclusion - **Overall Sentiment**: Positive outlook on growth opportunities in both contact lens and fertility markets, with a strong focus on operational efficiency and shareholder value creation [30][33]

Core Viewpoint - CooperCompanies has appointed Barbara Carbone as an independent director, effective May 1, 2025, enhancing its Board with her extensive experience in finance and human resources [1][2][3]. Company Overview - CooperCompanies is a leading global medical device company with two main business units: CooperVision, focused on contact lenses, and CooperSurgical, dedicated to fertility and women's healthcare [3]. - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over fifty million lives annually [3]. New Director's Background - Barbara Carbone has nearly four decades of experience, primarily at KPMG LLP, where she served as an Audit Partner for over 24 years [2]. - She has held significant roles, including Chairperson of the KPMG Partnership Audit Committee and National Partner in Charge for Human Resources [2]. - Currently, she chairs the Board of Directors of TrueCar, Inc., and serves on the boards of Limoneira Company and Bob's Discount Furniture [2].